
Viridian (VIRI) | Financial Analysis & Statements
Viridian Therapeutics, Inc. | Mid-cap | Energy
Viridian Therapeutics, Inc. | Mid-cap | Energy
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
1.2B
Gross Profit
340.2M
28.08%
Operating Income
202.4M
16.71%
Net Income
50.8M
4.19%
EPS (Diluted)
€6.93
Balance Sheet Metrics
Total Assets
2.8B
Total Liabilities
1.7B
Shareholders Equity
1.1B
Debt to Equity
1.53
Cash Flow Metrics
Operating Cash Flow
48.4M
Free Cash Flow
171.7M
Revenue & Profitability Trend
Viridian Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 1.2B | 1.1B | 927.4M | 1.1B | 886.7M |
Cost of Goods Sold | 871.2M | 817.4M | 654.9M | 853.2M | 726.5M |
Gross Profit | 340.2M | 258.4M | 272.5M | 209.8M | 160.2M |
Operating Expenses | 137.8M | 138.0M | 116.8M | 109.8M | 333.5M |
Operating Income | 202.4M | 120.4M | 155.7M | 100.0M | 41.2M |
Pre-tax Income | 50.1M | 19.9M | 83.5M | -186.1M | -346.8M |
Income Tax | 13.4M | 14.0M | 17.2M | -4.4M | 29.3M |
Net Income | 50.8M | 16.2M | 43.3M | -180.0M | -436.8M |
EPS (Diluted) | €6.93 | €2.00 | €6.00 | -€25.00 | -€62.00 |
Income Statement Trend
Viridian Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | 926.2M | 973.7M | 1.0B | 1.0B | 1.2B |
Non-Current Assets | 1.9B | 1.9B | 1.9B | 1.9B | 2.1B |
Total Assets | 2.8B | 2.9B | 2.9B | 2.9B | 3.4B |
Liabilities | |||||
Current Liabilities | 507.0M | 550.3M | 554.3M | 585.2M | 716.9M |
Non-Current Liabilities | 1.2B | 1.3B | 1.3B | 1.3B | 1.5B |
Total Liabilities | 1.7B | 1.9B | 1.8B | 1.9B | 2.2B |
Equity | |||||
Total Shareholders Equity | 1.1B | 1.1B | 1.1B | 1.0B | 1.2B |
Balance Sheet Composition
Viridian Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 36.1M | 3.9M | 47.8M | -181.6M | -407.9M |
Operating Cash Flow | 48.4M | 167.3M | 80.0M | -82.0M | -264.1M |
Investing Activities | |||||
Capital Expenditures | 6.8M | -60.5M | 40.5M | -54.9M | -63.6M |
Investing Cash Flow | -1.5M | -61.4M | 6.4M | 29.5M | -37.2M |
Financing Activities | |||||
Dividends Paid | - | - | - | - | - |
Financing Cash Flow | -59.3M | 22.2M | 12.6M | -67.2M | -5.1M |
Free Cash Flow | 171.7M | 176.3M | 85.7M | 109.8M | -38.8M |
Cash Flow Trend
Viridian Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
50.43
Forward P/E
5.52
Price to Book
0.40
Price to Sales
0.34
PEG Ratio
5.52
Profitability Ratios
Profit Margin
2.05%
Operating Margin
21.93%
Return on Equity
0.93%
Return on Assets
4.95%
Financial Health
Current Ratio
1.54
Debt to Equity
103.04
Beta
1.37
Per Share Data
EPS (TTM)
€1.15
Book Value per Share
€146.51
Revenue per Share
€170.52
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
viri | 415.4M | 50.43 | 0.40 | 0.93% | 2.05% | 103.04 |
Medincell S.A | 565.5M | -18.81 | - | 61.33% | -66.50% | -1.44 |
Valneva SE | 409.5M | 70.64 | 2.11 | -44.11% | -43.21% | 120.48 |
BNP Paribas Easy | 456.7M | 15.91 | - | -96.39% | -27.22% | 2.22 |
Abivax SA | 331.7M | -1.96 | -52.78 | -196.12% | 0.00% | -16.16 |
Inventiva S.A | 379.0M | -0.88 | -0.99 | 172.73% | 0.00% | -1.70 |
Financial data is updated regularly. All figures are in the company's reporting currency.